Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) is a major public health problem that has received increasing attention because of the high rate of associated cardiovascular morbidity and mortality. Mounting evidence indicates that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) safely slow down progression of CKD. There is also growing evidence supporting combination treatment of nephropathies with an ACE inhibitor plus an ARB to more completely block the RAAS and provide greater renoprotection than either an ACE inhibitor-based or ARB-based regimen. The National Kidney Foundation suggests that ACE inhibitors and ARBs may be used in combination to reduce proteinuria in patients with kidney disease; however, larger outcomes trials are needed.

Original languageEnglish (US)
Pages (from-to)372-380
Number of pages9
JournalAmerican Journal of Nephrology
Volume28
Issue number3
DOIs
StatePublished - Apr 2008

Fingerprint

Angiotensin Receptor Antagonists
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Renin-Angiotensin System
Kidney Diseases
Therapeutics
Proteinuria
Public Health
Morbidity
Kidney
Mortality
Pharmaceutical Preparations

Keywords

  • Angiotensin receptor blocker
  • Angiotensin-converting enzyme inhibitor
  • Chronic kidney disease
  • Combination therapy
  • Renin-angiotensin-aldosterone system

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{a957675560ad4dfc87c4c1a4947ed27b,
title = "Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease",
abstract = "Chronic kidney disease (CKD) is a major public health problem that has received increasing attention because of the high rate of associated cardiovascular morbidity and mortality. Mounting evidence indicates that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) safely slow down progression of CKD. There is also growing evidence supporting combination treatment of nephropathies with an ACE inhibitor plus an ARB to more completely block the RAAS and provide greater renoprotection than either an ACE inhibitor-based or ARB-based regimen. The National Kidney Foundation suggests that ACE inhibitors and ARBs may be used in combination to reduce proteinuria in patients with kidney disease; however, larger outcomes trials are needed.",
keywords = "Angiotensin receptor blocker, Angiotensin-converting enzyme inhibitor, Chronic kidney disease, Combination therapy, Renin-angiotensin-aldosterone system",
author = "Robert Toto and Palmer, {Biff F.}",
year = "2008",
month = "4",
doi = "10.1159/000112269",
language = "English (US)",
volume = "28",
pages = "372--380",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease

AU - Toto, Robert

AU - Palmer, Biff F.

PY - 2008/4

Y1 - 2008/4

N2 - Chronic kidney disease (CKD) is a major public health problem that has received increasing attention because of the high rate of associated cardiovascular morbidity and mortality. Mounting evidence indicates that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) safely slow down progression of CKD. There is also growing evidence supporting combination treatment of nephropathies with an ACE inhibitor plus an ARB to more completely block the RAAS and provide greater renoprotection than either an ACE inhibitor-based or ARB-based regimen. The National Kidney Foundation suggests that ACE inhibitors and ARBs may be used in combination to reduce proteinuria in patients with kidney disease; however, larger outcomes trials are needed.

AB - Chronic kidney disease (CKD) is a major public health problem that has received increasing attention because of the high rate of associated cardiovascular morbidity and mortality. Mounting evidence indicates that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) safely slow down progression of CKD. There is also growing evidence supporting combination treatment of nephropathies with an ACE inhibitor plus an ARB to more completely block the RAAS and provide greater renoprotection than either an ACE inhibitor-based or ARB-based regimen. The National Kidney Foundation suggests that ACE inhibitors and ARBs may be used in combination to reduce proteinuria in patients with kidney disease; however, larger outcomes trials are needed.

KW - Angiotensin receptor blocker

KW - Angiotensin-converting enzyme inhibitor

KW - Chronic kidney disease

KW - Combination therapy

KW - Renin-angiotensin-aldosterone system

UR - http://www.scopus.com/inward/record.url?scp=41849123818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849123818&partnerID=8YFLogxK

U2 - 10.1159/000112269

DO - 10.1159/000112269

M3 - Article

C2 - 18073461

AN - SCOPUS:41849123818

VL - 28

SP - 372

EP - 380

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 3

ER -